Contineum Therapeutics, Inc.
CTNMContineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications.
Table of contents
Earnings
Next report
Aug 4, 2026 (In 6 days)Competitors
Profile
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company leverages its drug discovery engine to target biological pathways associated with specific clinical impairments, aiming to restore function and alter disease progression. Its core value proposition lies in its ability to develop brain-penetrant, highly selective compounds for conditions with significant unmet medical needs.
A clinical-stage innovator with a validated LPA1R mechanism and a strategic partnership with a global pharmaceutical leader for its M1R program.
Questions, answered.
- What is Contineum Therapeutics, Inc.'s market cap?
- Contineum Therapeutics, Inc. (CTNM) has a market capitalization of $518.2M and trades on NASDAQ.
- Who are Contineum Therapeutics, Inc.'s competitors?
- Contineum Therapeutics, Inc.'s key competitors include Bristol-Myers Squibb, Pliant Therapeutics, Inc. Common Stock, Tenaya Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- Who does Contineum Therapeutics, Inc. partner with?
- Contineum Therapeutics, Inc.'s notable partners include Johnson & Johnson.
- Where is Contineum Therapeutics, Inc. headquartered?
- Contineum Therapeutics, Inc. is headquartered in United States of America. It has been publicly traded since 2024.